Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Total Valuation
Trevi Therapeutics has a market cap or net worth of $1.64B. The enterprise value is $510.02M.
Market Cap$1.64B
Enterprise Value$510.02M
Share Statistics
Trevi Therapeutics has 128,230,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding128,230,130
Owned by Insiders11.71%
Owned by Institutions55.53%
Financial Efficiency
Trevi Therapeutics’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -51.15%.
Return on Equity (ROE)-0.48
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-51.15%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee0.00
Profits Per Employee-1.55M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Trevi Therapeutics is ―. Trevi Therapeutics’s PEG ratio is -0.14.
PE Ratio―
PS Ratio0.00
PB Ratio4.18
Price to Fair Value4.18
Price to FCF-10.87
Price to Operating Cash Flow-37.42
PEG Ratio-0.14
Income Statement
In the last 12 months, Trevi Therapeutics had revenue of 0.00 and earned -47.91M in profits. Earnings per share was -0.47.
Revenue0.00
Gross Profit-147.00K
Operating Income-51.52M
Pretax Income-47.94M
Net Income-47.91M
EBITDA-47.79M
Earnings Per Share (EPS)-0.47
Cash Flow
In the last 12 months, operating cash flow was -44.01M and capital expenditures -19.00K, giving a free cash flow of -44.03M billion.
Operating Cash Flow-44.01M
Free Cash Flow-44.03M
Free Cash Flow per Share-0.34
Dividends & Yields
Trevi Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change201.18%
50-Day Moving Average11.38
200-Day Moving Average7.92
Relative Strength Index (RSI)54.28
Average Volume (3m)2.56M
Important Dates
Trevi Therapeutics upcoming earnings date is Mar 25, 2026, After Close (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 25, 2026
Ex-Dividend Date―
Financial Position
Trevi Therapeutics as a current ratio of 10.41, with Debt / Equity ratio of 0.43%
Current Ratio10.41
Quick Ratio10.41
Debt to Market Cap0.00
Net Debt to EBITDA0.69
Interest Coverage Ratio-12.88K
Taxes
In the past 12 months, Trevi Therapeutics has paid -30.00K in taxes.
Income Tax-30.00K
Effective Tax Rate<0.01
Enterprise Valuation
Trevi Therapeutics EV to EBITDA ratio is -8.02, with an EV/FCF ratio of -10.01.
EV to Sales0.00
EV to EBITDA-8.02
EV to Free Cash Flow-10.01
EV to Operating Cash Flow-10.02
Balance Sheet
Trevi Therapeutics has $194.93M in cash and marketable securities with $823.00K in debt, giving a net cash position of $194.10M billion.
Cash & Marketable Securities$194.93M
Total Debt$823.00K
Net Cash$194.10M
Net Cash Per Share$1.51
Tangible Book Value Per Share$0.99
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Trevi Therapeutics is $20.89, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$20.89
Price Target Upside55.09% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast15.84%